Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced that the U.S. Patent and Trademark Office has granted a patent covering its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with protection extending through April 2042.

The patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment using the DRP® test. The grant follows a Notice of Allowance the USPTO issued in April 2026.

Allarity also holds patent protection for the stenoparib DRP® in Europe and Australia through 2039, with related applications pending in additional international markets.

Stenoparib is an oral dual inhibitor of PARP1/2 and tankyrase 1/2 being evaluated primarily in ovarian cancer, with additional trials underway in small cell lung cancer. Allarity completed a Phase 2 trial in advanced ovarian cancer, and an amended protocol enrolling platinum-resistant or platinum-ineligible patients began in summer 2025. A separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer began enrolling patients in early 2026.

"With this U.S. patent now granted and providing protection into 2042, we have established an important long-term intellectual property foundation for stenoparib and our DRP® companion diagnostic," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics.